Several early phase trials are investigating the COX-2 inhibitor, celecoxib, as a radiosensitizer in a range of malignancies including prostate cancer [52], locally advanced non-small cell lung cancer [53], locally advanced cervical cancer [54], rectal cancer, and recurrent head and neck cancer [55]. The gene discussed is PTGS2; the disease is prostate cancer.